The same study highlighted that CPT1C downregulation led to breast cancer stromal remodeling and anthracycline resistance, suggesting that CPT1C could serve as a novel predictive biomarker for breast cancer chemotherapy [103]. This evidence concerns the gene CPT1C and breast cancer.